Skip to main content
Clinical Trials/NCT02176629
NCT02176629
Completed
Not Applicable

Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. MeMO-RV2

Centre Hospitalier Universitaire de Nice1 site in 1 country60 target enrollmentAugust 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
MCI
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
60
Locations
1
Primary Endpoint
Evaluate the acceptability of the RV
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Cognitive and memory problems characterize Alzheimer's disease (AD). Along with these disorders, psychological and behavioral symptoms (also known as neuropsychiatric symptoms) , as well as pathophysiological processes are frequently found and involved significantly in maintaining autonomy, prognosis and treatment of the disease. Apathy or disorder motivation is the most common disorder behavior and early stages of cognitive impairment. Apathy is particularly associated with cognitive difficulties such as attention deficit disorder - concentration.

In terms of prevention as term care , there is now a broad consensus that interventions on cognition and behavior must not be limited to pharmacological treatment but should also promote non-drug approaches.

Interest in video games (serious games and serious games) as intervention support rehabilitation is growing. Similarly, the virtual reality (VR) and the new information technologies and communications offer significant opportunities in terms of rehabilitation and therapeutic assistance.

This protocol is part of a European project to propose techniques for improving the treatment of people at risk of social exclusion ( VERVE project ) aims .

A first experiment conducted in 2013 showed the acceptability of Virtual Reality (VR) in healthy elderly subjects. In a second step , it is important to validate the feasibility of using the RV or in frail subjects with mild cognitive impairment or Alzheimer's disease in mild to moderate in a clinical environment.

This is a biomedical , randomized given to a group of patients with mild cognitive impairment or Alzheimer's disease & diseases associated with mild to moderate.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
February 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female age ≥ 60 years.
  • Introducing either:
  • MCI diagnosis (ICD-10)
  • diagnosis of Alzheimer's disease or mixed mild to moderate (ICD 10).
  • Subject undisturbed locomotion requiring the use of a walking aid.
  • Score at the Mini Mental Test (MMSE) between 16 and 28.

Exclusion Criteria

  • Presence of psychiatric disorders
  • Presence of eye diseases causing blurred vision can not be corrected with lenses or glasses.
  • Presence of auditory pathologies causing a significant decrease in hearing unaided.
  • High sensitivity to motion sickness.
  • migraine disease.
  • Subject epileptic.
  • Subject vulnerable

Outcomes

Primary Outcomes

Evaluate the acceptability of the RV

Time Frame: At the end of experience (45 min)

Analog scale assessment of satisfaction from 0 to 100% is given at the end of experience about that evaluates: * The general acceptability of the RV * His sense of security * The environment of RV * The degree of motivation

Secondary Outcomes

  • Evaluate the motivation of subjects (interest, cognition) is greater in the virtual environment during the VR experience compared to a conventional cognitive stimulation activity (CSC).(At the end of experience (45 min))

Study Sites (1)

Loading locations...

Similar Trials